In Lyons v. Premo Pharmaceutical Labs, Inc., 170 N.J. Super. 183, 406 A.2d 185 (App.Div.), certif. denied, 82 N.J. 267, 412 A.2d 774 (1979), the Court addressed the question of whether a "broker" of the drug DES could be strictly liable in tort for injuries sustained by the child of a woman who took the drug while she was pregnant. Id. at 188-89, 406 A.2d 185. While acknowledging that the broker was "in a sense, in the chain of distribution and contributed to placing the product in the stream of commerce," the Court ultimately determined that the broker "must be shown . . . to have exercised control over the product" in order to be held strictly liable for injuries caused by the product. Id. at 196-97, 406 A.2d 185. The Court concluded that the broker's role was that of a facilitator rather than an "active participant," noting that the broker never had physical control of the product and had merely arranged the sale. Id. at 196, 406 A.2d 185.